A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer.

Détails

ID Serval
serval:BIB_023D5F6C0BE2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer.
Périodique
Alimentary Pharmacology and Therapeutics
Auteur⸱e⸱s
Nichita C., Ciarloni L., Monnier-Benoit S., Hosseinian S., Dorta G., Rüegg C.
ISSN
1365-2036 (Electronic)
ISSN-L
0269-2813
Statut éditorial
Publié
Date de publication
2014
Volume
39
Numéro
5
Pages
507-517
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
BACKGROUND: Early detection and treatment of colorectal adenomatous polyps (AP) and colorectal cancer (CRC) is associated with decreased mortality for CRC. However, accurate, non-invasive and compliant tests to screen for AP and early stages of CRC are not yet available. A blood-based screening test is highly attractive due to limited invasiveness and high acceptance rate among patients.
AIM: To demonstrate whether gene expression signatures in the peripheral blood mononuclear cells (PBMC) were able to detect the presence of AP and early stages CRC.
METHODS: A total of 85 PBMC samples derived from colonoscopy-verified subjects without lesion (controls) (n = 41), with AP (n = 21) or with CRC (n = 23) were used as training sets. A 42-gene panel for CRC and AP discrimination, including genes identified by Digital Gene Expression-tag profiling of PBMC, and genes previously characterised and reported in the literature, was validated on the training set by qPCR. Logistic regression analysis followed by bootstrap validation determined CRC- and AP-specific classifiers, which discriminate patients with CRC and AP from controls.
RESULTS: The CRC and AP classifiers were able to detect CRC with a sensitivity of 78% and AP with a sensitivity of 46% respectively. Both classifiers had a specificity of 92% with very low false-positive detection when applied on subjects with inflammatory bowel disease (n = 23) or tumours other than CRC (n = 14).
CONCLUSION: This pilot study demonstrates the potential of developing a minimally invasive, accurate test to screen patients at average risk for colorectal cancer, based on gene expression analysis of peripheral blood mononuclear cells obtained from a simple blood sample.
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/03/2014 19:31
Dernière modification de la notice
20/08/2019 12:24
Données d'usage